Patents which claim the use of inhibitors/antagonists
(such as Abs, Abs Fragments, HMGB1 Fragments, Small Molecules) in
cardiovascular disorders related to HMGB1 over-expression:
MI
2001A000562 Granted in Italy WO02074337 Granted in Europe, Mexico
and Australia (Pending
in: Canada, Japan, China)
US 10/471,641 Granted in the USA
RM2004A00058 Granted in Italy WO2005074984 (Pending in: USA, Canada)
Patent which claims the use of HMGB1
inhibitors/antagonists to block Atherosclerotic Plaque Progression:
RM2005A000032 Granted in Italy
Patents which cover the use of HMGB1 and
its fragments in connective tissue regeneration: WO02074337 Granted in Europe, Mexico and Australia (Pending in: USA,
Canada, Japan, China)
Patents covering oral use of
Cysteine/Cystine (BIOCYSAN) in End Stage Renal Disease:
WO2005058305 Granted in
Europe and Mexico(Pending in: USA,
Canada, Japan) MI2003A002528 Granted in Italy
Patents covering oral use of
Cysteine/Cystina+Glutathione (BIOCYSAN Plus) use in End Stage Renal Disease:
WO2007116428 (Pending in: South Korea
, Mexico, Argentina)
RM2006A00206 Granted in Italy
Bio3 News...
Bio3 Research has recently been granted from USPTO the
US
patent # 10/471,641 which claims the use of HMGB1 inhibitors and antagonists for
the treatment of Cardiovascular Disorders…
